EGFR and neoplasm: The pharmacokinetic behavior of these SNAP photoimmunoconjugates using a preclinical mouse model was investigated and demonstrated to specifically and optimally accumulate in EGFR‐expressing tumor xenografts 10 h after injection, with complete renal clearance achieved at 72h [287].